{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:15Z","timestamp":1786987755515,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.diabres.2012.09.025","type":"journal-article","created":{"date-parts":[[2012,9,23]],"date-time":"2012-09-23T16:45:26Z","timestamp":1348418726000},"page":"436-444","source":"Crossref","is-referenced-by-count":9,"title":["The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food"],"prefix":"10.1016","volume":"98","author":[{"given":"Hans","family":"Ericsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Sj\u00f6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Heijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Dorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wollbratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensio","family":"Norjavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2012.09.025_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2012.09.025_bib0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","article-title":"Is glycaemic control improving in U.S. adults?","volume":"31","author":"Hoerger","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2012.09.025_bib0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2008-1073127","article-title":"Diabetes mellitus in German primary care: quality of glycaemic control and subpopulations not well controlled\u2014results of the DETECT study","volume":"117","author":"Huppertz","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.diabres.2012.09.025_bib0020","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","article-title":"Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study","volume":"32","author":"Banegas","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2012.09.025_bib0025","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2012.09.025_bib0030","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2012.09.025_bib0035","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2165\/00003495-200868150-00005","article-title":"New drugs for type 2 diabetes mellitus","volume":"68","author":"Krentz","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2012.09.025_bib0040","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","article-title":"Is the EASD\/ADA algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis","volume":"53","author":"Schernthaner","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2012.09.025_bib0045","first-page":"5","article-title":"Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database","volume":"11","author":"Berthet","year":"2011","journal-title":"Clin Pharm"},{"key":"10.1016\/j.diabres.2012.09.025_bib0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2850","article-title":"Assessing the potential for glucokinase activators in diabetes therapy","volume":"8","author":"Matschinsky","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.diabres.2012.09.025_bib0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/13543784.17.2.145","article-title":"Glucokinase activators in diabetes management","volume":"17","author":"Coghlan","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diabres.2012.09.025_bib0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1358\/dof.2009.034.08.1394557","article-title":"Glucokinase activators as potential antidiabetic agents possessing superior glucose-lowering efficacy","volume":"34","author":"Fyfe","year":"2009","journal-title":"Drugs Future"},{"key":"10.1016\/j.diabres.2012.09.025_bib0065","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc11-1200","article-title":"Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes","volume":"34","author":"Meininger","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2012.09.025_bib0070","doi-asserted-by":"crossref","unstructured":"Sj\u00f6strand M, Ericsson H, Hartford M, Leonsson-Zachrisson M, Norjavaara E, Eriksson JW. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Diabetes Obes Metab 2012 Sep 9. [Epub ahead of print].","DOI":"10.1111\/j.1463-1326.2012.01672.x"},{"key":"10.1016\/j.diabres.2012.09.025_bib0075","series-title":"Guidance for industry: food-effect bioavailability and fed bioequivalence studies","author":"Food and Drug Administration (U.S. Department of Health and Human Services)","year":"2002"},{"key":"10.1016\/j.diabres.2012.09.025_bib0080","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1210\/jc.2010-1041","article-title":"Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study","volume":"95","author":"Bonnadonna","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2012.09.025_bib0085","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2337\/diacare.24.7.1221","article-title":"Randomized dose ranging study of the reductions of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166)","volume":"24","author":"Gribble","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2012.09.025_bib0090","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1210\/jc.2003-031120","article-title":"Induction of \u03b2-cell rest by a Kir6.2\/SUR1-selective KATP-channel opener preserves \u03b2-cell insulin stores and insulin secretion in human islets cultured at high (11mM) glucose","volume":"89","author":"Ritzel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2012.09.025_bib0095","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1152\/ajpendo.2000.279.3.E520","article-title":"Overnight inhibition of insulin secretion restores pulsatility and proinsulin\/insulin ratio in type 2 diabetes","volume":"279","author":"Laedtke","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2012.09.025_bib0100","doi-asserted-by":"crossref","first-page":"s11","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes\u20142010","volume":"33","author":"American Diabetes Association (ADA).","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2012.09.025_bib0105","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/jc.2007-2000","article-title":"Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes","volume":"93","author":"Esposito","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2012.09.025_bib0110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc10-1141","article-title":"Impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular diastolic dysfunction","volume":"34","author":"Shimabukuro","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2012.09.025_bib0115","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"NAVIGATOR Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2012.09.025_bib0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822712003294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822712003294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:39:37Z","timestamp":1562200777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822712003294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0168822712003294"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2012.09.025","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}